ARTICLE SUMMARY:
Harrod discusses how MVM built a successful medtech investment strategy and its rationale for investing in Vertos Medical and Gynesonics, two successful exits this year, demonstrating MVM’s optimism about medtech investing overall.
Hugo Harrod is a partner at MVM Partners, an investment firm with a significant portfolio in medical devices, at a time when many life sciences venture capital firms are shying away from medical devices in favor of sectors with potential for greater returns and less risk. The firm has seen some significant exits in 2024, including the sale of Vertos Medical to Stryker in September for an undisclosed sum and the agreement to purchase Gynesonics by Hologic in October for $350 million, plus adjustments. Harrod was on the board of Vertos and was chair of the board of Gynesonics, and he guided MVM’s investment in those companies, the former of which took place in 2017 and the latter in October 2023.
